Erin O'Brien

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

What is new in research on major depressive disorder?

Report reviews key study results and provides updates on additional studies in development.

“We expect this antibody to be a valuable new weapon for fighting the opioid crisis.”

Awais Aftab, MD, interviews Audrey Clare Farley, PhD, author of Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

Investigators also concluded that rTMS may be effective as an adjunctive treatment for patients with MDD.

The FDA did not grant approval for the treatment for major depressive disorder.

Although ulotaront was well-tolerated, results for patients treated with it were not superior to those for patients treated with placebo.

"Systemic racism is insidious and ingrained in our daily experience. Women of color are doubly minoritized."

“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”

The drug has shown statistically significant, clinically meaningful reductions in symptoms of depression, anhedonia.

Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.

Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.

Researchers focused on elements across several categories, including brain state, cumulative exposure, and treatment and individualized parameters.

Although more than 90% of children had at least 1 caregiver-reported sleep problem, only 20% had a clinician-documented sleep problem.

The advisory identifies positive and negative effects of social media usage and next steps for making social media safer for youth.

Study investigates connections between rTMS and factors including depression and cognitive performance.

The risperidone formulation is the first FDA-approved treatment for this patient population to use technology enabling controlled release over time.

Treatment is now the first and only once-at-bedtime oxybate to be approved by the FDA for individuals with narcolepsy.

If approved, the drug will be the first FDA-approved treatment for agitation associated with Alzheimer dementia in the United States.

Public responses to mass shootings, in particular, often include speculations about the shooter’s mental state. But what is the real connection between gun violence and mental illness?

The AMA, substance abuse experts share their thoughts on this decision and what it means for psychiatric clinicians and their patients.

Study results show that the therapy activates serotonin (5-HT) and improves stress-coping ability.

Results show that the novel formulation of dexmethylphenidate can be taken either with or without food.

Leaders from across the United States aim to work together to develop bipartisan solutions for the youth mental health crisis.

The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.

The ongoing study demonstrated statistically significant improvements over baseline in comparison to results at 6 weeks.

What's the latest in dementia?

The novel atypical antipsychotic is already FDA-approved for the treatment of schizophrenia in adults.

Check out the best clinical pearls from the 2022 Neuroscience Education Institute (NEI) Congress!